For research and educational purposes only. Not medical advice.

Setmelanotide (Imcivree), the MC4R agonist for genetic obesity, and what its FDA label actually covers

Setmelanotide (Imcivree) is a selective MC4R agonist approved by the FDA on November 25, 2020 for chronic weight management in POMC, PCSK1, and…

Close-up of a laboratory PCR thermocycler chamber used in genetic testing

For research and educational purposes only. Not medical advice.

Category: Peptides. 8 min read. By pepSmart Editorial. .

Key takeaways

  • Setmelanotide (Imcivree, Rhythm Pharmaceuticals) was approved by the FDA on November 25, 2020 for chronic weight management in patients with obesity due to confirmed POMC, PCSK1, or LEPR deficiency .
  • On June 16, 2022 the FDA expanded the label to include Bardet-Biedl syndrome (BBS). On December 26, 2024 the FDA further expanded the indicated age range, lowering the lower-age boundary from 6 years to 2 years for the labeled rare-disease populations .
  • The pivotal Phase 3 evidence is two single-arm trials with placebo-controlled withdrawal periods. The Clement 2020 program (Lancet Diabetes and Endocrinology) reported clinically meaningful weight reduction in POMC and LEPR deficiency. Haqq 2022 (Lancet Diabetes and Endocrinology) reported reduction in body weight and hunger scores in BBS .
  • Setmelanotide is a selective MC4R agonist. It is approved only for the listed rare-disease populations and is not indicated for general obesity, common polygenic obesity, or weight management without a confirmed qualifying genotype .
  • The label includes warnings for skin hyperpigmentation and pre-existing nevi darkening, depression and suicidal ideation, spontaneous penile erections in male patients, and disturbance in sexual arousal in female patients .

What Imcivree is

Setmelanotide is a synthetic cyclic 8-residue peptide analog of the endogenous melanocortin alpha-MSH. It binds the melanocortin family of receptors with selectivity for MC4R, the hypothalamic receptor responsible for the satiety-and-energy-expenditure leg of the leptin-melanocortin pathway. Rhythm Pharmaceuticals developed and markets the drug as Imcivree under the brand pathway approved in the United States .

The label is narrow by design. The drug is approved for chronic weight management in patients with obesity due to a confirmed single-gene defect in the leptin-melanocortin pathway upstream of MC4R, or in Bardet-Biedl syndrome, which disrupts MC4R signaling through ciliary biology. The FDA approval pathway recognized that these conditions produce severe, early-onset obesity driven by a specific receptor-pathway defect that an MC4R agonist can address directly .

The leptin-melanocortin pathway in one paragraph

Leptin secreted from adipocytes acts on the leptin receptor (LEPR) on POMC neurons in the hypothalamic arcuate nucleus. Those POMC neurons cleave proopiomelanocortin (POMC) into alpha-melanocyte-stimulating hormone (alpha-MSH) and related peptides through the action of prohormone convertase 1 (PCSK1). Alpha-MSH binds MC4R on downstream second-order neurons, which integrate satiety and energy-expenditure signals. Genetic defects at LEPR, POMC, or PCSK1 break the upstream side of this pathway and produce severe, early-onset obesity. Setmelanotide bypasses the upstream block by directly agonizing MC4R .

Pivotal trial readouts: POMC, LEPR, and BBS

The pivotal Phase 3 program for the 2020 approval consisted of two open-label trials of setmelanotide in patients with biallelic POMC or PCSK1 deficiency (n=10) and biallelic LEPR deficiency (n=11), with a placebo-controlled withdrawal period in each trial. Clement K, van den Akker E, Argente J, et al. published the results in Lancet Diabetes and Endocrinology in 2020 .

In the POMC trial, 8 of 10 patients (80 percent) achieved at least 10 percent body weight loss at approximately 1 year on setmelanotide. In the LEPR trial, 5 of 11 patients (about 45 percent) achieved at least 10 percent body weight loss at approximately 1 year. Hunger scores measured on a standardized 11-point most-hunger scale decreased substantially in both trials. The placebo-controlled withdrawal period in each trial showed that body weight rose and hunger scores worsened when drug was withdrawn and reversed when drug was reintroduced, supporting the causal attribution to setmelanotide .

The BBS expansion was supported by a Phase 3 trial published by Haqq AM, Chung WK, Dollfus H, et al. in Lancet Diabetes and Endocrinology in 2022. The trial enrolled 38 patients with genetically confirmed BBS or Alstrom syndrome and reported a primary endpoint of about 32 percent of BBS patients achieving at least 10 percent body weight loss at 52 weeks on the open-label segment, with significant reductions in hunger scores. The Alstrom subgroup did not reach the same threshold, and the label approval was specific to BBS .

Dose, administration, and patient selection

Setmelanotide is administered as a subcutaneous injection once daily in the morning. The labeled adult dosing starts at 1 mg subcutaneously once daily for 2 weeks, then escalates as tolerated to a typical maintenance dose between 2 mg and 3 mg daily, with the exact target individualized to weight response and tolerability. Pediatric dosing is weight-banded; the December 2024 label expansion lowered the floor to age 2 years for the rare-disease indications .

Patient selection requires confirmed biallelic variants at POMC, PCSK1, or LEPR (interpreted as pathogenic, likely pathogenic, or of uncertain significance per the label) or a confirmed clinical diagnosis of Bardet-Biedl syndrome. Genetic testing through Rhythm's Uncovering Rare Obesity program is the typical ascertainment route, and the label is explicit about the role of confirmed genotype in patient selection. The drug is not indicated for heterozygous carriers, for patients with common polygenic obesity, or for empirical trial-of-therapy use without confirmed genotype .

Safety profile and label warnings

The most commonly reported adverse reactions in the pivotal trials were injection-site reactions, skin hyperpigmentation, nausea, headache, diarrhea, and vomiting. The label discusses several specific warnings that prescribers and patients should be aware of .

  • Skin hyperpigmentation and darkening of pre-existing nevi. The label recommends full-body skin examinations before therapy and periodically during therapy, given MC1R-mediated melanocyte activation by an MC4R agonist that is not perfectly selective.
  • Depression and suicidal ideation. The label warns that some patients in the program reported these events; prescribers should monitor and discontinue if these emerge.
  • Spontaneous penile erections in male patients and disturbance in sexual arousal in female patients. Counseling on these reactions is recommended before therapy initiation.
  • Risk in benzyl-alcohol-sensitive infants. The injection contains benzyl alcohol as a preservative; the label includes the standard neonatal warning.
  • Hepatic impairment. Setmelanotide is not recommended in severe hepatic impairment.

What the label does not cover

Setmelanotide is not approved for common polygenic obesity, for monogenic conditions beyond the listed indications, for syndromic obesity outside BBS, or for heterozygous carriers of POMC, PCSK1, or LEPR variants. Phase 2 work has explored additional MC4R-pathway conditions, including MC4R deficiency and other hypothalamic obesities, but the published evidence does not support a label-level claim of efficacy in those populations at the time of writing .

Community framing of setmelanotide as a general-purpose MC4R weight-loss drug runs ahead of the label. The drug is unlikely to be priced or available outside the rare-disease channel, and the safety profile (skin pigmentation in particular, plus the psychiatric warning) shapes how the molecule is used clinically. The relevant comparator for general obesity remains the GLP-1 receptor agonist and incretin co-agonist class, not an MC4R agonist .

Research framing and disclaimer

Setmelanotide is the strongest current example of a peptide drug developed and approved for a rare, mechanism-identified obesity population. The Phase 3 trials are small but precise, and the regulatory framework around them is unusually clean: a confirmed genotype identifies the patient, a selective MC4R agonist supplies the missing ligand, and a placebo-controlled withdrawal period within each trial supports the causal attribution.

For research and educational purposes only. Not medical advice. Decisions about setmelanotide therapy involve confirmed genetic testing, specialized clinical evaluation, and a careful review of dermatologic and psychiatric history. The drug is a specialty-prescribing molecule in a defined rare-disease channel, not a general weight-loss therapy.

Related tools

References

  1. [1] FDA Approves First Treatment for Weight Management for People with Certain Rare Genetic Conditions (Imcivree, setmelanotide, November 25, 2020) (FDA)
  2. [2] FDA: Imcivree (setmelanotide) supplemental approval for Bardet-Biedl syndrome (June 16, 2022) (FDA)
  3. [3] DailyMed: IMCIVREE (setmelanotide) injection prescribing information (DailyMed)
  4. [4] Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020 (PubMed)
  5. [5] Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome (Phase 3). Lancet Diabetes Endocrinol 2022 (PubMed)
  6. [6] ClinicalTrials.gov: setmelanotide Phase 3 trial in POMC or LEPR deficiency (ClinicalTrials.gov)
  7. [7] ClinicalTrials.gov: setmelanotide Phase 3 trial in Bardet-Biedl syndrome (ClinicalTrials.gov)
  8. [8] ClinicalTrials.gov search: setmelanotide other MC4R-pathway conditions (ClinicalTrials.gov)
  9. [9] PubMed search: leptin melanocortin MC4R pathway pediatric obesity review (PubMed)